Cafedrine

DB12926InvestigationalSmall molecule

Cafedrine is under investigation in clinical trial NCT01311414 (Effect of Cafedrine/Theodrenaline and Urapidil on Cerebral Oxygenation).

Mechanism: Pharmacologically active on Beta-1 adrenergic receptor and Cyclic nucleotide phosphodiesterase
Curator reviewed
Formula / weight: C₁₈H₂₃N₅O₃ · 357.414 g/mol (avg)

Resolves to

Compound

Clinical / RWD

Structure

InChIKeyUJSKUDDDPKGBJY-WFASDCNBSA-NSMILESC[C@H](NCCN1C=NC2=C1C(=O)N(C)C(=O)N2C)[C@H](O)C1=CC=CC=C1

Targets

What you can answer from here — as of August 27, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

610Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 17 drug categories

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cafedrine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.